Cabaletta Bio (CABA) Liabilities and Shareholders Equity (2018 - 2025)

Cabaletta Bio's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $165.1 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 10.79% year-over-year to $165.1 million in Q4 2025; TTM through Dec 2025 was $744.5 million, a 12.14% decrease from a year earlier, with the FY2025 full-year figure at $165.1 million, down 10.79% from the prior year.
• Liabilities and Shareholders Equity declined to $165.1 million in Q4 2025 per CABA's latest filing, from $189.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $253.6 million in Q4 2023 and bottomed at $91.7 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $165.1 million (2025), against an average of $159.7 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 132.44% in 2024 and plunged 31.32% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $126.3 million in 2021, then declined by 7.42% to $117.0 million in 2022, then jumped by 116.85% to $253.6 million in 2023, then declined by 27.05% to $185.0 million in 2024, then slipped by 10.79% to $165.1 million in 2025.
• Per Business Quant, the three latest CABA Liabilities and Shareholders Equity figures stand at $165.1 million (Q4 2025), $189.8 million (Q3 2025), and $224.5 million (Q2 2025).